bone regeneration
direct bone growth
versatile bone system
bone tissue engineering
non-union bone defects
system safe
bone critical size defect
rhBMP2
clinical applications
safer delivery of recombinant human bone morphogenetic protein
Current clinical delivery
powerful human growth factor
robust polymer-based system
clinical use
FN
Translational synergistic growth factor microenvironments
PEA
higher doses
technology
high doses
licensed Taragenyx
commercialisation
integrin binding region
non-degradable material
integrin binding domain of fibronectin
GF receptors
functional material
tissue morphogenesis
bulk polymer
translational standpoint
potential applications
engineered systems
effective presentation of GFs
current commercial products
degradable construct spray
direct stem cell differentiation
patients
co-localised signalling
combination
serious complications
vascularisation
ethyl acrylate
synergy
lower rhBMP
nanometric layer
murine model
major hurdle
appraisal
integrins
ability of Poly
ERC Grant
proposal
Meek
planning stages
Results
exploitation
route
patent
SME
scaling
surgeon